Haferlach Torsten, Kohlmann Alexander, Kern Wolfgang, Hiddemann Wolfgang, Schnittger Susanne, Schoch Claudia
Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany.
Semin Hematol. 2003 Oct;40(4):281-95. doi: 10.1016/s0037-1963(03)00193-8.
The standard methods to diagnose leukemia are cytomorphology and, in some cases, histology, which both are supplemented by cytochemistry and multiparameter immunophenotyping. Cytogenetics, fluorescence in situ hybridisation (FISH), and polymerase chain reaction (PCR) assays add important information and allow comprehensive diagnosis of well-defined subentities today. In the clinic, better understanding of the course of distinct, biologically defined disease subtypes is the basis for a selection of specific therapeutic approaches. As knowledge on deregulated pathways in leukemia accelerates the development of new therapeutics, a detailed and comprehensive diagnostic tool is required. The microarray technology that quantifies gene expression intensities of thousands of genes in a single analysis has the potential to become essential for the molecular classification of leukemias. Microarrays may be used routinely for diagnostic purposes in the near future. Gene expression profiling should also lead to the detection of new biological and clinically relevant subtypes in leukemia and therefore guide therapeutic decisions.
诊断白血病的标准方法是细胞形态学,在某些情况下还包括组织学,这两者都由细胞化学和多参数免疫表型分析作为补充。细胞遗传学、荧光原位杂交(FISH)和聚合酶链反应(PCR)检测提供了重要信息,使得如今能够对明确的亚实体进行全面诊断。在临床上,更好地了解不同的、生物学定义的疾病亚型的病程是选择特定治疗方法的基础。随着对白血病中失调通路的认识加速了新疗法的开发,需要一种详细而全面的诊断工具。微阵列技术能够在一次分析中对数千个基因的表达强度进行量化,有可能成为白血病分子分类的关键手段。在不久的将来,微阵列可能会常规用于诊断目的。基因表达谱分析还应能检测白血病中新的生物学和临床相关亚型,从而指导治疗决策。